Trials / Unknown
UnknownNCT03987698
Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma
Phase II Clinical Study of PD-1 Monoclonal Antibody Combination With Autologous Cytokine-induced Killer Cell Immunotherapy in the Second-line Treatment of Metastatic Clear Cell Renal Cell Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This randomized, multicenter,open-label, phase II study is to evaluate the effects of PD-1 inhibitor combination with autologous cytokine-induced killer cell immunotherapy in the second-line treatment of patients with metastatic clear cell renal cell carcinoma.
Detailed description
In the experimental group, patients received Camrelizumab injection (SHR-1210) 200mg d1, CIK cells 1x10\^10 d14; Q3W, for 4 cycles; then Camrelizumab injection maintenance treatment for 2 years. In the control group, patients received Camrelizumab injection 200mg d1, Q3W, for 2 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SHR-1210 | SHR-1210 injection |
| BIOLOGICAL | CIK cells | CIK cells injection |
Timeline
- Start date
- 2019-06-01
- Primary completion
- 2022-06-01
- Completion
- 2022-06-01
- First posted
- 2019-06-17
- Last updated
- 2020-07-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03987698. Inclusion in this directory is not an endorsement.